Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 3
2002 12
2003 7
2004 12
2005 27
2006 22
2007 22
2008 17
2009 17
2010 37
2011 50
2012 50
2013 52
2014 51
2015 53
2016 58
2017 55
2018 58
2019 38
2020 62
2021 64
2022 68
2023 91
2024 47

Text availability

Article attribute

Article type

Publication date

Search Results

878 results

Results by year

Filters applied: . Clear all
Page 1
Roflumilast.
[No authors listed] [No authors listed] 2024 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2024 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 32352702 Free Books & Documents. Review.
No information is available on the use of roflumilast in nursing mothers. The drug and its metabolite are more than 97% bound to plasma proteins, so amounts in milk are likely to be very low. ...
No information is available on the use of roflumilast in nursing mothers. The drug and its metabolite are more than 97% bound to plas …
Topical roflumilast for the treatment of psoriasis.
Drakos A, Vender R, Torres T. Drakos A, et al. Expert Rev Clin Immunol. 2023 Jul-Dec;19(9):1053-1062. doi: 10.1080/1744666X.2023.2219897. Epub 2023 May 30. Expert Rev Clin Immunol. 2023. PMID: 37243575 Review.
Roflumilast's mechanism of action and pharmacokinetic profile are also discussed. ...In the future, real-world data and active comparator trials with existing non-steroidal agents are needed to better understand roflumilast's place in the current treatment landscape …
Roflumilast's mechanism of action and pharmacokinetic profile are also discussed. ...In the future, real-world data and active compar …
Roflumilast.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2022 Nov 22;79(23):2086-2087. doi: 10.1093/ajhp/zxac249. Am J Health Syst Pharm. 2022. PMID: 36197808 No abstract available.
Roflumilast.
[No authors listed] [No authors listed] 2018 Jun 4. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2018 Jun 4. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643522 Free Books & Documents. Review.
Roflumilast is a selective inhibitor of phosphodiesterase-4 (PDE-4) that has unique antiinflammatory activity and is used to treat and prevent exacerbations of chronic obstructive pulmonary disease (COPD). Roflumilast has not been linked to significant serum enzyme …
Roflumilast is a selective inhibitor of phosphodiesterase-4 (PDE-4) that has unique antiinflammatory activity and is used to treat an …
Topical Roflumilast for Plaque Psoriasis.
O'Toole A, Gooderham M. O'Toole A, et al. Skin Therapy Lett. 2023 Sep;28(5):1-4. Skin Therapy Lett. 2023. PMID: 37734074 Free article. Review.
Roflumilast is a highly selective phosphodiesterase-4 inhibitor for the treatment of plaque psoriasis. Topical roflumilast 0.3% cream, approved by the US FDA and Health Canada for use in adolescents and adults, has proven efficacy and tolerability. ...
Roflumilast is a highly selective phosphodiesterase-4 inhibitor for the treatment of plaque psoriasis. Topical roflumilast 0.3 …
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
Lebwohl MG, Kircik LH, Moore AY, Stein Gold L, Draelos ZD, Gooderham MJ, Papp KA, Bagel J, Bhatia N, Del Rosso JQ, Ferris LK, Green LJ, Hebert AA, Jones T, Kempers SE, Pariser DM, Yamauchi PS, Zirwas M, Albrecht L, Devani AR, Lomaga M, Feng A, Snyder S, Burnett P, Higham RC, Berk DR. Lebwohl MG, et al. JAMA. 2022 Sep 20;328(11):1073-1084. doi: 10.1001/jama.2022.15632. JAMA. 2022. PMID: 36125472 Free PMC article.
The incidence of treatment-emergent adverse events was 25.2% with roflumilast vs 23.5% with vehicle in trial 1 and 25.9% with roflumilast vs 18.4% with vehicle in trial 2. The incidence of serious adverse events was 0.7% with roflumilast vs 0.7% with vehicle …
The incidence of treatment-emergent adverse events was 25.2% with roflumilast vs 23.5% with vehicle in trial 1 and 25.9% with rofl …
Roflumilast: A potential drug for the treatment of cognitive impairment?
Sugin LJS, Murugesan A, Bindu M, Sunil KN. Sugin LJS, et al. Neurosci Lett. 2020 Sep 25;736:135281. doi: 10.1016/j.neulet.2020.135281. Epub 2020 Jul 28. Neurosci Lett. 2020. PMID: 32735939 Review.
The beneficial effects of roflumilast on cognition are believed to be mediated through the above-mentioned cellular effects. Recently, Jabaris et al had shown that roflumilast has improved the short and long-term memory in rodents. ...
The beneficial effects of roflumilast on cognition are believed to be mediated through the above-mentioned cellular effects. Recently …
Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Martinez FJ, et al. Lancet. 2015 Mar 7;385(9971):857-66. doi: 10.1016/S0140-6736(14)62410-7. Epub 2015 Feb 13. Lancet. 2015. PMID: 25684586 Clinical Trial.
BACKGROUND: Roflumilast reduces exacerbations in patients with severe chronic obstructive pulmonary disease. ...Adverse events were reported by 648 (67%) of 968 patients receiving roflumilast and by 572 (59%) of 967 patients in the placebo group; adverse event-assoc …
BACKGROUND: Roflumilast reduces exacerbations in patients with severe chronic obstructive pulmonary disease. ...Adverse events were r …
Roflumilast: a review of its use in the treatment of COPD.
Wedzicha JA, Calverley PM, Rabe KF. Wedzicha JA, et al. Int J Chron Obstruct Pulmon Dis. 2016 Jan 6;11:81-90. doi: 10.2147/COPD.S89849. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 26792988 Free PMC article. Review.
Roflumilast has a variety of anti-inflammatory effects including decreasing inflammatory mediators and the expression of cell surface markers and inhibition of apoptosis. ...Data suggest that roflumilast reduces moderate to severe exacerbations with the benefit most …
Roflumilast has a variety of anti-inflammatory effects including decreasing inflammatory mediators and the expression of cell surface …
Roflumilast for COPD.
Izquierdo JL, Aparicio J. Izquierdo JL, et al. Drugs Today (Barc). 2010 Nov;46(11):823-31. doi: 10.1358/dot.2010.46.11.1521831. Drugs Today (Barc). 2010. PMID: 21225021 Review.
The results of clinical trials indicated that in patients with COPD associated with chronic bronchitis and a history of exacerbations, roflumilast improves lung function and reduces the frequency of exacerbations that require medical interventions. This effect remained whe …
The results of clinical trials indicated that in patients with COPD associated with chronic bronchitis and a history of exacerbations, ro …
878 results